Form 4: Guardant Health Exec Reports Stock Transactions

AmirAli Talasaz, Co-Chief Executive Officer and Director of Guardant Health, Inc., reported transactions involving common stock and restricted stock units.

Summary

• AmirAli Talasaz, Co-Chief Executive Officer and Director of Guardant Health, Inc., reported several transactions on June 30, 2026, and July 1, 2026.
• On June 30, 2026, 2,817 shares of common stock were acquired with a transaction code 'M' (conversion or exercise of derivative or other security) and a price of $0. This acquisition is related to restricted stock units and results in 1,884,153 shares held indirectly by the Talasaz and Eskandari 2017 Family Trust.
• Also on June 30, 2026, 1,428 shares of common stock were disposed of with a transaction code 'F' (payment of exercise price or withholding of securities) at a price of $150.03, leaving 1,882,725 shares held indirectly by the trust.
• On July 1, 2026, 23,997 shares of common stock were acquired with a transaction code 'M' and a price of $0, increasing the indirect holdings to 1,906,722 shares.
• Another acquisition of 9,715 shares of common stock occurred on July 1, 2026, with a transaction code 'M' and a price of $0, bringing the indirect holdings to 1,916,437 shares.
• On the same day, July 1, 2026, 17,086 shares of common stock were disposed of with a transaction code 'F' at a price of $170.77, resulting in 1,899,351 shares held indirectly by the trust.
• The filing also details the vesting of restricted stock units: 2,817 RSUs granted on March 17, 2026, vest in quarterly installments; 23,997 RSUs granted on March 18, 2024, vest over three years with a portion vesting on January 1, 2025, and the remainder quarterly; and 9,715 RSUs granted on March 12, 2025, vest over three years with a portion vesting on January 1, 2026, and the remainder quarterly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it primarily details routine insider stock transactions related to RSU vesting and tax obligations, rather than significant strategic or financial performance indicators.

Positives

• Acquisition of 2,817 shares of common stock on June 30, 2026, valued at $0, likely due to RSU vesting.
• Acquisition of 23,997 shares of common stock on July 1, 2026, valued at $0, likely due to RSU vesting.
• Acquisition of 9,715 shares of common stock on July 1, 2026, valued at $0, likely due to RSU vesting.

Negatives

• Disposal of 1,428 shares of common stock on June 30, 2026, at a price of $150.03.
• Disposal of 17,086 shares of common stock on July 1, 2026, at a price of $170.77.

Future Outlook

The filing does not contain forward-looking statements or guidance. It reports on past transactions.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions and do not inherently signal strategic shifts. The reported transactions appear to be related to RSU vesting and tax withholding, which are common occurrences for executives.

Related Party Transactions

• Shares held by Talasaz and Eskandari 2017 Family Trust.

Stakeholder Impact

• Shareholders: The transactions reported are by an insider and do not directly indicate a change in the company's fundamental value, but they do reflect the compensation structure for executives.

Key Dates

Keywords

Guardant Health, GH, Form 4, Insider Trading, Stock Transaction, AmirAli Talasaz, Restricted Stock Units, Common Stock, Beneficial Ownership, SEC Filing